Coronavirus Update: CoVIg-19 Alliance Ends As Trial Misses Endpoints

Plus: India Production Deals For RDIF

 
• By Scrip Team

Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment. 

immunoglobulin
Trial Outcome Dashes Hopes For Alliance's Hyperimmune Immunoglobulin • Source: Alamy

The Phase III Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) trial, sponsored and funded by the US National Institute of Allergy and Infectious Diseases (NIAID) and supported by the plasma company-founded CoVIg-19 Plasma Alliance, has missed its endpoints.

Analyses remain ongoing and NIAID and its funded INSIGHT Network said they will publish the full results soon

More from COVID-19

More from Scrip